National Provider Identifier 1811991284 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
524
Part D claims
$57,066
Total drug cost
22
Distinct drugs
135
Beneficiaries (≥)
Highest-cost drugs prescribed
Drug
Claims
Drug cost
Mounjaro(Tirzepatide)
17
$17,657
Ozempic(Semaglutide)
12
$15,126
Trelegy Ellipta(Fluticasone/Umeclidin/Vilanter)
22
$14,176
Tradjenta(Linagliptin)
12
$5,948
Ondansetron Odt(Ondansetron)
126
$617
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Source:CMS Medicare Part D·Snapshot DY2024
Quality
MIPS quality score
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Standing
Medicare enrollmentNo PECOS enrollment record found for this NPISource:CMS PECOS·Snapshot 2026
Compromised-flag (federal monitoring/penalties)No monitored-compliance or CMS penalty flag on record (OIG CIA, CMS Civil Money Penalties checked)Source:OIG CIA · CMS CMP·Snapshot 2026
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
Graph relationships
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.